$LQDA

Khindri Sanjeev sold $85K of LQDA

Khindri Sanjeev (Chief Development Officer) sold 1,185 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khindri Sanjeev
Published Jul 15, 2026, 12:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosed transaction is an open-market sale of 1,185 shares at about $71.51 weighted average, executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may treat this as routine insider selling with limited incremental information, but it can be used to monitor insider behavior trends.

03

What to watch

The article does not state whether additional sales/purchases occurred around the same period beyond the two trades listed, nor does it provide context on total compensation or prior sale cadence.

Relevance 2/10Novelty 4/10Timing: SEC Form 4 filed 2026-07-14, covering a sale executed 2026-07-13.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by an officer (Chief Development Officer).

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia insider Khindri Sanjeev, Chief Development Officer, sold $84,740 of LQDA shares via a Rule 10b5-1 plan on 2026-07-13.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely short-lived.

Evidence & confidence

The filing is a disclosed open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no accompanying fundamental catalyst (earnings, guidance, trial, deal, or regulatory action).

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with internal views on timing or liquidity needs, so traders may still watch for follow-on insider activity or changes in guidance.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Khindri Sanjeev

    Chief Development Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as Yes, indicating the sale was scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient